Orthopedic Implants and Devices: Global Regulation and Registration

For every regulator below we answer the three questions device teams ask first: what class is my implant, how long will it take, and what will it cost.

What are orthopedic implants?

Orthopedic implants are devices surgically placed to replace, support, or reinforce the musculoskeletal system — bones, joints, and the spine. The category spans total joint replacements (hip, knee, and shoulder), trauma fixation hardware (bone plates, screws, intramedullary nails, and external fixators), spinal systems (interbody fusion cages, pedicle screw constructs, and artificial discs), and the surgical instruments and bone cements used to place them. FDA groups these device types under 21 CFR Part 888. Support and mobility products worn outside the body — braces, casts, and orthopedic footwear — are separate, generally lower-risk devices, and standalone software that plans or navigates a procedure is regulated on its own rather than as the implant.

The regulatory catch is that risk class depends on the specific implant and the market, not just the device type. The same hip stem can clear as a Class II 510(k) device in the United States, sit at Class III in Europe, and register as Class III or IV in Brazil. Our market-access research found that a single orthopedic implant can carry up to seven different risk-class labels across the markets we cover, which is why a structured classification analysis in each target market is the first deliverable of any serious program. The full breakdown is in our orthopedic implant market-access report.

Every cost below has two parts: the government fee, and our own flat annual service fee per market, from US$1,000 per year in the US (device listing and US Agent representation) and from US$2,000 per year in most other markets. Exact current figures live in our pricing calculator.

FDA orthopedic implant regulation (United States)

FDA regulates orthopedic implants through the same risk-based framework as other devices, under the orthopedic device rules in 21 CFR Part 888, with implant-specific expectations layered on top: biocompatibility, mechanical and fatigue testing, and long-term safety evidence for anything that stays in the body.

• Classification. Most trauma and joint hardware — bone screws, plates, intramedullary nails, and standard hip and knee systems — is Class II and clears through a 510(k) against a predicate device. Higher-risk designs, including certain spinal implants such as artificial discs and metal-on-metal total hips, are Class III and require a PMA. FDA lists the orthopedic device types under 21 CFR Part 888, and a qualification memo settles which pathway applies before you file.
• Timeline. A 510(k) typically runs 3 to 9 months end to end including preparation and FDA interaction; a PMA program for a Class III implant plans for well over a year. A Pre-Submission meeting adds a few weeks up front and routinely saves review cycles later.
• Cost. Government fees: US$26,067 for a standard 510(k) review (US$6,517 for qualified small businesses), plus US$11,423 per year in establishment registration; a PMA runs far higher. Our flat US$1,000 per year covers FDA establishment registration and device listing maintenance plus US Agent representation; 510(k) preparation and submission are scoped as a separate project.

Custom-made and 3D-printed orthopedic implants

Patient-matched and 3D-printed implants sit in their own regulatory lane. In the US, a genuinely one-off device can qualify for FDA's custom device exemption, but most "custom" implants are patient-matched devices that still need a 510(k) or PMA, with validation of the additive-manufacturing process. The EU MDR treats custom-made devices under Annex XIII, a separate conformity route from CE marking, with its own documentation and post-market obligations. We map each product to the right definition before it drives the wrong submission.

Start from our United States market page for the full FDA pathway.

EU MDR orthopedic implants: classification and CE marking

Under the EU Medical Device Regulation (MDR 2017/745), orthopedic implants are among the most tightly controlled device types, and a notified body sits in the middle of every timeline. Rule 8 sets the class, and the higher the class the deeper the clinical and technical scrutiny.

• Classification. Under MDR Rule 8, implantable orthopedic devices are generally Class IIb, but total and partial joint replacements — hip, knee, and shoulder — are Class III, as are implants that come into contact with the spinal column. A notified body reviews the technical documentation for every class, and Class III adds deeper clinical evaluation.
• Timeline. Plan 12 to 24 months with a notified body for a first certification, driven by notified body capacity and the maturity of your technical documentation, clinical evaluation, and mechanical test evidence.
• Cost. There is no central government fee; the money goes to the notified body — typically €30,000 to €70,000 across a first certification cycle, higher for the Class III total joints and spinal implants, plus annual surveillance — and to building MDR-grade documentation. Our EU Authorized Representative service is a flat annual fee from US$2,000, capped at US$4,000 as your portfolio grows, and covers EC REP representation, document review, and EUDAMED support; CE-marking work with your notified body is scoped separately.

MDR also layers implant-specific obligations on top of classification: clinical investigations are the default for Class III and implantable devices (Article 61(4)), a public Summary of Safety and Clinical Performance goes into EUDAMED for implantable and Class III devices (Article 32), and patients must receive an implant card (Article 18). The carve-out that matters for trauma hardware: well-established devices — bone screws, wedges, plates, wires, and pins — are exempt from both the implant card and the default clinical-investigation requirement (Articles 18(3) and 61(6)(b)), provided the clinical evaluation rests on sufficient clinical data.

Spinal implants: where orthopedic devices reach Class III

Spinal hardware is where classification climbs. Interbody fusion cages and other implants in contact with the spinal column, along with total disc replacements, are Class III under MDR Rule 8, while pedicle screws, plates, and rods stay at Class IIb. In the US, most posterior pedicle screw systems and fusion cages are Class II, but artificial discs are Class III PMA devices. PEEK and titanium construction, subsidence and expulsion testing, and MRI compatibility are the evidence themes reviewers focus on. If your portfolio spans fixation and motion-preservation devices, expect them to split across classes in every market.

Notified body strategy should shape your EU plan early; see the European Union market page for the MDR route.

Orthopedic implant registration in Brazil and Latin America (ANVISA)

Brazil is the anchor of any Latin American strategy, and ANVISA regulates orthopedic implants as higher-risk devices under RDC 751/2022; Mexico's COFEPRIS is the region's second gate. Both require a local representative — we act as your Brazil Registration Holder without taking control of your registration.

• Classification. RDC 751 classifies devices I-IV on the IMDRF risk model. Implantable orthopedic hardware is generally Class III, and the highest-risk implants reach Class IV; both require full registro (registration) rather than the streamlined notificação, together with B-GMP certification of the manufacturing site.
• Timeline. Class III-IV registration plans for 6 to 12 months, and the B-GMP inspection can add lead time if your site is not yet certified. In Mexico, COFEPRIS runs 6 to 12 months, faster where reliance on an FDA or CE approval applies.
• Cost. ANVISA government fees: implant families in Class III-IV run R$8,510 to R$19,856 to register, plus a one-time international B-GMP certification of R$72,805 where required. Mexico's COFEPRIS charges MX$16,499 to MX$30,798 per product by class. Our registration service starts at US$3,000 per year for high-risk implants in both markets.

Start with the Brazil market page; labeling, instructions for use, and submissions are prepared natively in Portuguese and Spanish.

Orthopedic implant registration in Asia-Pacific: Singapore first, then ASEAN

Most overseas implant makers enter Asia-Pacific through Singapore: HSA works in English, follows the IMDRF model, and rewards a strong FDA or CE dossier with a fast abridged review. A Singapore approval then anchors expansion across ASEAN — Malaysia, Thailand, Indonesia, Vietnam, and the Philippines — where reliance-friendly frameworks make each additional market incremental rather than a new program. Japan and Korea are the region's big mature prizes with their own systems and languages. China is the largest market but the hardest entry — local type testing, its own clinical expectations, and the longest timelines — so treat it as its own program when the business case justifies it, not as a default stop.

• Classification. Singapore's HSA uses risk classes A through D, and implantable orthopedic devices land in Class C or D; ASEAN members track the same IMDRF-style model. Japan classifies implants as highly controlled medical devices, generally Class III against JMDN codes; Korea's MFDS uses Classes I-IV. China places orthopedic implants in Class III, its highest tier.
• Timeline. HSA abridged evaluation with a reference approval closes in 2 to 6 months; ASEAN registrations typically run 3 to 9 months per market on the same dossier. Japan plans for 9 to 14 months via PMDA, Korea 6 to 12 months including KGMP, and China 12 to 24 months including local type testing.
• Cost. Singapore's government fees are light: a SGD 560 application plus SGD 2,010 to SGD 6,250 evaluation by class. ASEAN peers are similar (Malaysia MYR 500 application plus MYR 750 to MYR 3,000 registration; Thailand THB 3,100 to THB 21,000, with a THB 53,000 expert review where required). Japan's PMDA review fees start around ¥1 million; China's NMPA registration fee for an imported Class III device is RMB 308,800, before type-testing costs. Our registration service starts at US$2,000 per year in much of ASEAN (US$3,000 for high-risk implants in Singapore, Malaysia, and Thailand); China, Japan, and Korea are quoted flat per market on the same model.

One well-built reference dossier does most of the region's work — sequencing is the strategy. See the Singapore, Malaysia, Thailand, Japan, South Korea, and China market pages.

Orthopedic implant registration in Saudi Arabia and MENA (SFDA)

The Gulf is one of the fastest-growing regions in our portfolio, and its regulators are built around reliance: a strong FDA, CE, or other reference approval does most of the work when the dossier is assembled correctly. SFDA regulates orthopedic implants explicitly and requires a local Authorized Representative.

• Classification. SFDA classifies orthopedic implants into risk classes A through D on the IMDRF model, in most cases mirroring your reference-market class. The UAE's MOHAP and other MENA authorities likewise lean on the reference approval's classification.
• Timeline. With a reference approval in hand, SFDA marketing authorization (MDMA) typically closes in 2 to 6 months, and UAE registration runs a similar range. Without a reference approval, expect materially longer.
• Cost. Government fees across the Gulf are modest — generally a few thousand US dollars' equivalent per authority — so the real spend is dossier assembly, Arabic labeling where required, and local representation. We quote MENA registration programs flat per market, on the same transparent model as our calculator markets.

See the Saudi Arabia and UAE market pages; we run the wider region under one program.

Evidence, quality system, and lifecycle

Orthopedic implants live in the body for years, so the evidence bar is built around durability and biological safety. We run an ISO 13485 quality system and assemble the test package regulators expect: biocompatibility to ISO 10993 for the implant's material and surface, mechanical and fatigue testing to the device-specific ASTM and ISO standards (hip stems, knee systems, spinal constructs, and bone-fixation hardware each have their own), wear and corrosion data, sterilization validation, and MRI-safety evaluation for anything that stays implanted. Clinical evidence is planned once and reused across FDA, EU MDR, and APAC submissions, and MDR-grade clinical evaluation is written to stand up in front of a notified body. After launch, implant registries, complaint handling, and vigilance reporting keep every registration current and feed the post-market surveillance that MDR and most other markets now require.

One program, every major market

A global orthopedic program is a sequencing problem: pick the anchor market, build the technical file and clinical evidence once, and reuse the classification analysis, test reports, and QMS artifacts everywhere else. We run the full program for orthopedic implant manufacturers from a single team — strategy, submissions, in-country representation, and post-market maintenance — with transparent government fees and timelines in our pricing calculator.